Veterinary Blog
Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates
Choosing Love and Compassion
This is a big and stressful moment for the country. We want to take a moment to acknowledge that for all of us.
Reflecting on 2020
At FidoCure®, we were fortunate to make progress on our mission to advance canine cancer treatment, despite the challenges of 2020.
Introducing the New Veterinarian Portal Dashboard
Not only are we working hard to expand our canine cancer toolbox, we’re continually working to improve the user experience for veterinarians.
Featuring
Unique Perspective: Cancer Biologist & Pet Cancer Parent
When your dog has cancer and you're also a world-renowned cancer researcher, your interactions with veterinary oncologists are a little different.
Introducing Olaparib to the FidoCure® Veterinary Oncology Toolbox
Another exciting addition to the FidoCure® oncology toolbox: Olaparib as a new targeted therapy.
Safety and Toxicity of Small Molecule Inhibitors in Dogs with Spontaneously Occurring Malignancies — The Use of Real World Data
The VCS Virtual Conference was held from October 15 - 17, 2020. We had the honor of presenting our abstract during the event.
Introducing Palbociclib: A New Targeted Therapy
We are thrilled to announce a new targeted therapy, Palbociclib, as part of the FidoCure® oncology toolbox.
ProductFeaturing
Great Danes to Grandads: Comparative Cancer and Aging Research
Dr. Ehrhart shares insight from her current work in comparative aging research and highlights its intersection with cancer and musculoskeletal research in veterinary medicine.
WebinarsHSA Genomic Data: FidoCure® and Mason
On August 13, 2020, FidoCure® hosted a webinar with Dr. Nicola Mason, B.Vet.Med, PhD, DACVIM (Internal Medicine).
DataTargeted Therapy Efficacious Dose Finding: The Case for Agile Design
Why is the Palladia dose used at the clinic often different from the one on the FDA-approved label? Over 100 human targeted therapies have been approved, yet many doses were found to be incorrect in the post market stage. Why is that?
Data
